Cytokine Release Syndrome: Current Perspectives

被引：119

作者：

Murthy, Hemant ^{[1
,2
]}

Iqbal, Madiha ^{[1
,2
]}

Chavez, Julio C. ^{[3
]}

Kharfan-Dabaja, Mohamed A. ^{[1
,2
]}

机构：

[1] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd,Mangurian Bdg 3rd Floor, Jacksonville, FL 32224 USA

[2] Mayo Clin, Blood & Marrow Transplantat Program, 4500 San Pablo Rd,Mangurian Bdg 3rd Floor, Jacksonville, FL 32224 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA

来源：

IMMUNOTARGETS AND THERAPY | 2019年 / 8卷

关键词：

cytokine release syndrome; chimeric antigen receptor T-cell therapy; T-CELL THERAPY; A(3) ADENOSINE RECEPTOR; ANTIBODY; IL-6; MANAGEMENT; SAFETY; REMISSIONS; TOXICITIES; BIOMARKERS; SERUM;

D O I：

10.2147/ITT.S202015

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chimeric antigen receptor T cell (CART) therapy represents a novel and a paradigm-shifting approach to treating cancer. Recent clinical successes have widened the applicability of CD19 CART cells for the treatment of relapsed/refractory B-cell NHL, namely tisagenleclucel and axicabtagene ciloleucel. Tisagenleclucel is also approved for relapsed and/or refractory B-ALL up to age 25. CART therapy is associated with unique and potentially life-threatening toxicities, notably cytokine release syndrome (CRS). A better understanding of the pathogenesis of CRS is crucial to ensure proper management. In this review, CRS definitions, profiles, risk factors and grading systems are discussed. Finally, current and novel investigational approaches and therapies for CRS are summarized.

引用

页码：43 / 52

页数：10

共 50 条

[1] Current concepts in the diagnosis and management of cytokine release syndrome
Lee, Daniel W.
Gardner, Rebecca
Porter, David L.
Louis, Chrystal U.
Ahmed, Nabil
Jensen, Michael
Grupp, Stephan A.
Mackall, Crystal L.
BLOOD, 2014, 124 (02) : 188 - 195
[2] Cytokine release syndrome
Cookson, Emma
LANCET HAEMATOLOGY, 2022, 9 (05): : E322 - E322
[3] Cytokine release syndrome
Shimabukuro-Vornhagen, Alexander
Goedel, Philipp
Subklewe, Marion
Stemmler, Hans Joachim
Schloesser, Hans Anton
Schlaak, Max
Kochanek, Matthias
Boell, Boris
von Bergwelt-Baildon, Michael S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[4] STAT CYTOKINE RELEASE SYNDROME
Dickman, Erin
CLINICAL JOURNAL OF ONCOLOGY NURSING, 2020, 24 (04) : 456 - 456
[5] Understanding cytokine release syndrome
Goedel, Philipp
Shimabukuro-Vornhagen, Alexander
von Bergwelt-Baildon, Michael
INTENSIVE CARE MEDICINE, 2018, 44 (03) : 371 - 373
[6] BelimumabSeizures and cytokine release syndrome
Reactions Weekly, 2024, 2003 (1) : 164 - 164
[7] Rituximab and Cytokine Release Syndrome
Kulkarni, Hrishikesh S.
Kasi, Pashtoon Murtaza
CASE REPORTS IN ONCOLOGY, 2012, 5 (01): : 134 - 140
[8] Modeling cytokine release syndrome
Cliona Rooney
Tim Sauer
Nature Medicine, 2018, 24 : 705 - 706
[9] Understanding cytokine release syndrome
Philipp Gödel
Alexander Shimabukuro-Vornhagen
Michael von Bergwelt-Baildon
Intensive Care Medicine, 2018, 44 : 371 - 373
[10] Advances in the prediction of cytokine release syndrome
Harper, Kirsty
TOXICOLOGY LETTERS, 2014, 229 : S9 - S9

← 1 2 3 4 5 →